Physician profile
Anton G Beffa
NPI 1306815345
$4,915.92
in general payments reported to CMS, 2019-2025
26 companies · $735 in 2025
The $735 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $448 · 2021: $873 · 2022: $754 · 2023: $729 · 2024: $797 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,243 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,243.20 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $931.92 | 2019-2025 | Hydrus Microstent, Clareon, Tryptyr |
| Allergan, INC. | $484.50 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $472.44 | 2021-2025 | Acthar |
| Bausch & Lomb Americas INC. | $418.95 | 2023-2025 | Xiidra, Miebo, Vyzulta |
| Glaukos Corporation | $345.99 | 2023 | Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Abbvie INC. | $272.98 | 2022-2025 | Durysta, Lumigan, Vuity |
| Tarsus Pharmaceuticals, INC. | $239.10 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $235.57 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $217.64 | 2019-2023 | |
| Oyster Point Pharma, INC. | $209.90 | 2022-2024 | Tyrvaya |
| Eyevance Pharmaceuticals LLC | $193.08 | 2020-2023 | Flarex |
| Sun Pharmaceutical Industries INC. | $183.73 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $167.08 | 2019-2021 | |
| Thea Pharma INC. | $98.99 | 2023-2025 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $85.54 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $57.00 | 2019-2020 | |
| Sight Sciences, INC. | $53.27 | 2019 | |
| Dompe US, INC. | $52.90 | 2025 | Oxervate |
| New World Medical,INC. | $51.99 | 2022-2024 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
| Harrow Eye, LLC | $44.61 | 2023-2025 | Iheezo, Vevye |
| Shire North American Group INC | $21.07 | 2019 | |
| Rayner Intraocular Lenses Limited | $19.72 | 2023 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Horizon Therapeutics Plc | $17.13 | 2023 | Tepezza |
| Eyepoint US, INC. | $14.77 | 2019 | |
| Kala Pharmaceuticals, INC. | $13.08 | 2019 | |
| Ocular Therapeutix, INC. | $12.97 | 2023 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anton Beffa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.